Clinical Trial Update: A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State [Phase 2]

View source ↗

Summary

Phase 2 safety study evaluating elsubrutinib, upadacitinib, or their combination (ABBV-599) in adults with moderately to severely active systemic lupus erythema…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Elsubrutinib (elsubrutinib)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 2 | Status: COMPLETED | Results posted: 2025-01-14